Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
NVO Novo Nordisk A/S daily Stock Chart
NVO [NYSE]
Novo Nordisk A/S
Healthcare | Drug Manufacturers - Other | Denmark
financial highlights | statements
Index- P/E19.12 EPS (ttm)2.55 Insider Own26.40% Shs Outstand2.00B Perf Week-2.44%
Market Cap97.41B Forward P/E17.37 EPS next Y2.80 Insider Trans0.00% Shs Float1.25B Perf Month-3.49%
Income6.31B PEG2.52 EPS next Q- Inst Own8.40% Short Float0.10% Perf Quarter-13.70%
Sales18.49B P/S5.27 EPS this Y2.80% Inst Trans-0.33% Short Ratio0.81 Perf Half Y-1.30%
Book/sh3.37 P/B14.45 EPS next Y5.77% ROA38.90% Target Price60.40 Perf Year34.51%
Cash/sh1.56 P/C31.21 EPS next 5Y7.60% ROE82.20% 52W Range35.77 - 58.37 Perf YTD-9.30%
Dividend1.28 P/FCF27.62 EPS past 5Y14.60% ROI74.60% 52W High-18.36% Beta0.67
Dividend %2.63% Quick Ratio1.00 Sales past 5Y7.40% Gross Margin84.20% 52W Low33.23% ATR0.77
Employees42076 Current Ratio1.30 Sales Q/Q-5.30% Oper. Margin43.80% RSI (14)36.81 Volatility0.97% 1.38%
OptionableYes Debt/Eq0.03 EPS Q/Q-3.00% Profit Margin34.10% Rel Volume0.99 Prev Close48.68
ShortableYes LT Debt/Eq0.00 EarningsMay 02 BMO Payout278.60% Avg Volume1.55M Price47.65
Recom1.00 SMA20-3.18% SMA50-5.21% SMA200-3.67% Volume834,853 Change-2.11%
Dec-29-17Upgrade JP Morgan Underweight → Neutral
Dec-06-17Upgrade BofA/Merrill Neutral → Buy
Dec-01-17Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-25-17Downgrade Exane BNP Paribas Outperform → Neutral
Sep-06-17Upgrade BofA/Merrill Underperform → Neutral
Oct-31-16Downgrade DNB Markets Buy → Hold
Oct-31-16Downgrade Citigroup Buy → Neutral
Oct-28-16Downgrade BofA/Merrill Neutral → Underperform
Sep-23-16Initiated Piper Jaffray Neutral
Sep-13-16Upgrade Exane BNP Paribas Neutral → Outperform
Sep-09-16Downgrade JP Morgan Overweight → Neutral
Sep-01-16Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-31-16Upgrade HSBC Securities Reduce → Hold
Aug-08-16Downgrade BofA/Merrill Buy → Neutral
Aug-28-15Initiated Leerink Partners Mkt Perform $56
Jun-09-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-15-15Initiated Societe Generale Sell
May-28-13Upgrade Deutsche Bank Sell → Hold
Mar-31-10Initiated Deutsche Bank Hold
Mar-30-10Downgrade Mehta Partners Outperform → Market Perform
Apr-18-18 03:02PM  Xultophy® approved in Canada for the treatment of adults with type 2 diabetes CNW Group
Apr-11-18 08:00AM  Novo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in Canada CNW Group
08:00AM  Novo Nordisk announces the availability of Zonovate® for the treatment of patients with hemophilia A in Quebec CNW Group
Apr-06-18 05:35PM  Novo Nordisk Obtains Licence for Sickle Cell Disease Program Zacks
Apr-05-18 09:42AM  Novo Nordisk buys blood drug licence to boost anaemic biopharma business Reuters
Apr-03-18 08:16AM  Status regarding Novo Nordisk's holding of its own shares (31 March 2018) GlobeNewswire
Mar-28-18 07:35AM  Market Trends Toward New Normal in Novo Nordisk A/S, Brookfield Asset Management, Dun & Bradstreet, Goldcorp, NorthStar Asset Management Group, and IMAX Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Mar-23-18 11:53AM  These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status Investor's Business Daily
Mar-22-18 12:47PM  30 Most Obese Countries In The World in 2018: Biggest Anti-Obesity Drug Markets Insider Monkey
10:59AM  Drugmaker Novo Nordisk looks to former oil boss to energise M&A Reuters
Mar-21-18 09:59AM  Novo Nordisk Poised on Strong Pipeline Amid Competition Zacks
Mar-15-18 09:45AM  Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns Zacks
Mar-05-18 08:00AM  OZEMPIC® now available for Canadians with type 2 diabetes PR Newswire
Mar-02-18 03:00AM  Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices Bloomberg Video
03:00AM  Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices Bloomberg
Feb-28-18 07:01AM  [$$] Novo to invest $165m in first superbug venture fund Financial Times
04:33AM  Novo Holdings launches $165 million 'superbug' drug venture fund Reuters
03:36AM  Novo Holdings launches $165 million 'superbug' drug venture fund Reuters
Feb-27-18 09:38AM  Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP Zacks
Feb-23-18 09:11AM  Todays Biotech Movers: Sangamo Therapeutics, Inc. (NASDAQ:SGMO) And Novo Nordisk A/S (ADR) (NYSE:NVO) Market Exclusive
Feb-22-18 05:39AM  Novo Nordisk successfully kicks off final-stage trials for first diabetes pill Reuters
Feb-21-18 11:52AM  Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope Reuters
08:18AM  Eurozone Beats United States Again: 5 Hot Stock Picks Zacks
Feb-20-18 08:07AM  The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal Zacks
Feb-16-18 04:00PM  Top Research Reports for Novo Nordisk, TJX Companies & Cigna Zacks
Feb-14-18 08:55PM  5 More Stocks to Buy to Feed the Bear Motley Fool
11:14AM  FDA approves insulin dose calculator that's connected to a smartphone app CNBC
Feb-12-18 07:10AM  Blog Exposure - Novo Nordisks Ozempic is Approved in the EU for the Treatment of Type 2 Diabetes ACCESSWIRE
05:31AM  GlaxoSmithKline plc -- Moody's: M&A greatest downside risk to European pharma companies' credit quality in 2018 Moody's
Feb-06-18 04:30PM  Novo Nordisk's Dichotomy Abounds Motley Fool
10:19AM  FOCUS-In diabetes war, Novo Nordisk aims to break mould with new pill Reuters
Feb-05-18 02:32PM  Novo Nordisk plans $65M expansion in Johnston County American City Business Journals
08:14AM  Foreign Stock Roundup: RDS.A & AZN Impress, NVO & BABA Disappoint Zacks
07:20AM  Wired News Teva Pharma Announced the Acceptance of Fremanezumabs Marketing Authorization Application by EMA ACCESSWIRE
Feb-03-18 02:32PM  3 Top Obesity-Drug Stocks to Consider Buying Now Motley Fool
Feb-01-18 01:16PM  Novo Nordisk Is on High But Shaky Ground Bloomberg -6.54%
12:13PM  Germanys DAX ends sharply lower as global bond yields keep climbing MarketWatch
10:43AM  Novo Nordisk posts 4Q profit Associated Press
08:49AM  Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat Zacks
06:21AM  Novo Nordisk CEO welcomes Amazon, Berkshire, JPMorgan pharma company Reuters
05:22AM  Novo Nordisk CEO Is 'Quite Optimistic' About 2018 Growth Bloomberg Video
Jan-30-18 09:46AM  Company News For Jan 30, 2018 Zacks
09:21AM  Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B Zacks
08:52AM  Why Novo Nordisk (NVO) Might Surprise This Earnings Season Zacks
Jan-29-18 08:07PM  Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom Reuters
01:59PM  Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done TheStreet.com
12:54PM  Sanofi Beats Out Novo Nordisk in Bid to Buy Ablynx GuruFocus.com
12:15PM  Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom Reuters
12:14PM  Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom Reuters
11:41AM  Sanofi Pays 112% Premium for Ablynx Bloomberg Video
10:59AM  France's Sanofi buys biotech company Ablynx for $4.8 billion Associated Press
10:20AM  Sanofi beats Novo to buy Ablynx for 3.9 billion euros in biotech M&A boom Reuters
08:46AM  Sanofi's $16 Billion Splurge Leaves Novo Behind on Blood Deals Bloomberg
08:04AM  INTERVIEW: Novo Nordisk remains on hunt for biopharma deals Reuters
07:52AM  Novo Nordisk remains on hunt for biopharma deals Reuters
02:39AM  Sanofi Leapfrogs Novo With $4.8 Billion Cash Bid for Ablynx Bloomberg
12:00AM  Born From Frozen Camel Blood, Ablynx Is $4.8 Billion Prize Bloomberg
Jan-23-18 09:03AM  Reading the Estimates for Novartiss Alcon in 4Q17 Market Realist
07:34AM  Whats Expected of Novartiss Sandoz Segment in 4Q17? Market Realist
Jan-22-18 11:30AM  Behind Novartiss 4Q17 Estimates: Innovative Medicines Market Realist
10:00AM  Behind Novartiss 4Q17 Earnings: Why Some Expect Revenue Growth Market Realist
Jan-19-18 08:43AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis Zacks
Jan-18-18 12:33PM  Scoop Up Teva Pharmaceutical Industries Ltd (ADR) on Every Dip InvestorPlace
07:38AM  Largest Ablynx investor would consider improved Novo Nordisk bid Reuters
Jan-17-18 09:36AM  Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It? Zacks
Jan-16-18 12:06PM  Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade Benzinga
Jan-15-18 09:55AM  Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU Zacks
Jan-12-18 12:25PM  Three Diabetes Clinical Trials to Watch in 2018 GuruFocus.com
07:41AM  Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference Zacks
Jan-11-18 08:01AM  Why is Novo Nordisk Stock Up More Than 50% in Past Year? Zacks
07:35AM  How Is Bioverativs Eloctate Positioned Now? Market Realist
07:33AM  How Is Roches Hemlibra Positioned for 2018? Market Realist
Jan-10-18 02:18PM  Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know Motley Fool
09:39AM  Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes Zacks
Jan-09-18 09:58AM  Novo Nordisk Confirms Bid for Ablynx But Faces Rejection Zacks
08:00AM  Ozempic® approved in Canada for the treatment of adults with type 2 diabetes PR Newswire
08:00AM  Ozempic® approved in Canada for the treatment of adults with type 2 diabetes CNW Group
12:57AM  [$$] Belgiums Ablynx Rejects Novo Nordisk Bid The Wall Street Journal
Jan-08-18 01:00PM  Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid Reuters
12:54PM  Ablynx soars after rejects Novo Nordisk's $3.1 bln biotech bid Reuters
12:52PM  Novo Nordisk revises up offer for Ablynx to $3.1 billion Associated Press
10:45AM  Novo Nordisk Makes Unsolicited Bid for Ablynx TheStreet.com
10:26AM  [$$] Belgium's Ablynx Rejects Novo Nordisk Bid The Wall Street Journal
09:01AM  Ozempic Could Boost Novo Nordisks Revenue Growth in 2018 Market Realist
07:33AM  How Did Novo Nordisks NovoMix and Human Insulin Perform in 2017? Market Realist
07:32AM  In Drug Deals, $3.1 Billion Isn't Exactly Full-Blooded Bloomberg
07:26AM  ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS GlobeNewswire
04:19AM  Novo Nordisk bids $3.1 billion for Belgian biotech group Ablynx Reuters
03:58AM  Novo Nordisk submits proposal to buy biopharmaceutical fi... CNBC Videos
01:01AM  Novo Goes Public With $3.1 Billion Bid to Pressure Ablynx Bloomberg
Jan-07-18 09:09AM  5 Biggest New Drugs of 2018 -- and How You Can Profit From Their Makers Motley Fool
Jan-05-18 10:35AM  How Novo Nordisks Biopharmaceuticals Segment Performed in 3Q17 Market Realist
09:05AM  How Did Novo Nordisks Victoza and Saxendra Perform in 3Q17? Market Realist
07:37AM  How Did Novo Nordisks Modern Insulin Segment Perform in 3Q17? Market Realist
Jan-04-18 06:28PM  3 Large-Cap Pharma Stocks to Watch Out for This New Year Zacks
06:05PM  Novo Nordisks Xultophy, Ryzodeg, and Fiasp Could Boost Revenue Growth in 2018 Market Realist
04:35PM  How Is Novo Nordisks New Generation Insulin Segment Positioned after 3Q17? Market Realist
03:00PM  How Novo Nordisk Performed in 3Q17 Market Realist
Jan-03-18 09:49AM  Can Merck Regain its Mojo in 2018 After an Unimpressive '17? Zacks
03:07AM  5 Reasons to Invest in Novo Nordisk (NVO) Stock Right Now Zacks
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
open in yahoo | open in reuters | open in google